AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial.
Abstract | BACKGROUND: METHODS: An open-label phase III randomised controlled non-inferiority trial conducted in five countries in sub-Saharan Africa: Botswana, Malawi, South Africa, Uganda and Zimbabwe. The trial will compare CM induction therapy with (1) a single dose (10 mg/kg) of L-AmB given with 14 days of fluconazole (1200 mg/day) and flucytosine (100 mg/kg/day) to (2) seven days amphotericin B deoxycholate (1 mg/kg/day) given alongside seven days of flucytosine (100 mg/kg/day) followed by seven days of fluconazole (1200 mg/day). The primary endpoint is all-cause mortality at ten weeks with a non-inferiority margin of 10% and 90% power. Secondary endpoints are early fungicidal activity, proportion of grade III/IV adverse events, pharmacokinetic parameters and pharmacokinetic/pharmacodynamic associations, health service costs, all-cause mortality within the first two and four weeks, all-cause mortality within the first ten weeks (superiority analysis) and rates of CM relapse, immune reconstitution inflammatory syndrome and disability at ten weeks. A total of 850 patients aged ≥ 18 years with a first episode of HIV-associated CM will be enrolled (425 randomised to each arm). All patients will be followed for 16 weeks. All patients will receive consolidation therapy with fluconazole 800 mg/day to complete ten weeks of treatment, followed by fluconazole maintenance and ART as per local guidance. DISCUSSION: A safe, sustainable and easy to administer regimen of L-AmB that is non-inferior to seven days of daily amphotericin B deoxycholate therapy may reduce the number of adverse events seen in patients treated with amphotericin B deoxycholate and shorten hospital admissions, providing a highly favourable and implementable alternative to the current WHO recommended first-line treatment. TRIAL REGISTRATION: ISRCTN, ISRCTN72509687 . Registered on 13 July 2017.
|
Authors | David S Lawrence, Nabila Youssouf, Síle F Molloy, Alexandre Alanio, Melanie Alufandika, David R Boulware, Timothée Boyer-Chammard, Tao Chen, Francoise Dromer, Admire Hlupeni, William Hope, Mina C Hosseinipour, Cecilia Kanyama, Oliver Lortholary, Angela Loyse, David B Meya, Mosepele Mosepele, Conrad Muzoora, Henry C Mwandumba, Chiratidzo E Ndhlovu, Louis Niessen, Charlotte Schutz, Katharine E Stott, Duolao Wang, David G Lalloo, Graeme Meintjes, Shabbar Jaffar, Thomas S Harrison, Joseph N Jarvis |
Journal | Trials
(Trials)
Vol. 19
Issue 1
Pg. 649
(Nov 23 2018)
ISSN: 1745-6215 [Electronic] England |
PMID | 30470259
(Publication Type: Clinical Trial Protocol, Journal Article)
|
Chemical References |
- Antifungal Agents
- liposomal amphotericin B
- Amphotericin B
- Fluconazole
- Flucytosine
|
Topics |
- Africa South of the Sahara
- Amphotericin B
(administration & dosage, adverse effects, economics, pharmacokinetics)
- Antifungal Agents
(administration & dosage, adverse effects, economics, pharmacokinetics)
- Clinical Trials, Phase III as Topic
- Cost-Benefit Analysis
- Cryptococcus neoformans
(drug effects, pathogenicity)
- Drug Administration Schedule
- Drug Costs
- Drug Therapy, Combination
- Equivalence Trials as Topic
- Fluconazole
(administration & dosage)
- Flucytosine
(administration & dosage)
- Humans
- Induction Chemotherapy
- Meningitis, Cryptococcal
(drug therapy, economics, microbiology, mortality)
- Multicenter Studies as Topic
- Time Factors
- Treatment Outcome
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|